Huang L J, Hour M J, Teng C M, Kuo S C
Graduate Institute of Pharmaceutical Chemistry, China Medical College, Taichung, Taiwan.
Chem Pharm Bull (Tokyo). 1992 Sep;40(9):2547-51. doi: 10.1248/cpb.40.2547.
A series of new 1- and 2-arylmethyl-3,4-dimethylpyrano[2,3-c]pyrazol-6-one derivatives were synthesized and examined for their antiplatelet activities. Some of these compounds showed significant inhibitory activities. Among them, 1-phenylmethyl-3,4-dimethylpyrano[2,3-c]pyrazol-6(1H)-one (4a), 2-(2'-methoxyphenyl)methyl-3,4-dimethylpyrano[2,3-c]pyrazol-6(2H)- one (3e) and 2-(3'-methoxyphenyl)methyl-3,4-dimethylpyrano[2,3-c]pyrazol-6-(2H) - one (3f) were the most effective. These inhibitors acted in a concentration-dependent manner. The antiplatelet effect of compound 3f is due to the inhibition of thromboxane A2 formation and the blockade of thromboxane A2/prostaglandin endoperoxide receptor in washed rabbit platelets.
合成了一系列新的1-和2-芳基甲基-3,4-二甲基吡喃并[2,3-c]吡唑-6-酮衍生物，并对其抗血小板活性进行了研究。其中一些化合物表现出显著的抑制活性。其中，1-苯甲基-3,4-二甲基吡喃并[2,3-c]吡唑-6(1H)-酮（4a）、2-(2'-甲氧基苯基)甲基-3,4-二甲基吡喃并[2,3-c]吡唑-6(2H)-酮（3e）和2-(3'-甲氧基苯基)甲基-3,4-二甲基吡喃并[2,3-c]吡唑-6-(2H)-酮（3f）最为有效。这些抑制剂呈浓度依赖性作用。化合物3f的抗血小板作用是由于抑制了血栓素A2的形成以及阻断了洗涤兔血小板中的血栓素A2/前列腺素内过氧化物受体。
